Exclusive License. Subject to the terms of this Agreement, including [Section 5.1.2] and [Section 5.1.3], on a Licensed Development Candidate-by-Licensed Development Candidate basis, effective upon the applicable License Effective Date, MTEM, for itself and its Affiliates, hereby grants to BMS an exclusive (even as to MTEM and its Affiliates), royalty-bearing license, with the right to grant sublicenses as provided in [Section 5.1.2], under the MTEM Licensed Know-How and MTEM Licensed Patents to Exploit such Licensed Development Candidate(s) and corresponding Licensed Products Directed to the corresponding Collaboration Target in the Field in the Territory. ​.

Exclusive License. Subject to the terms and conditions of this Agreement, on an Allogene Target-by-Allogene Target basis, [[Cellectis:Organization]] hereby grants to Allogene and its Affiliates an exclusive (even as to [[Cellectis:Organization]]) license under the Licensed [[Cellectis:Organization]] Intellectual Property (excluding ​ Patent Rights), to make, have made, use, have used, sell, have sold, offer for sale, have offered for sale, import, have imported and otherwise exploit and Commercialize Allogene Licensed Products in the Field in the Territory, with the right to sublicense as provided in Section 4.1.4 (the “License”).

Exclusive License Grant. Subject to the provisions of this Agreement, Bioeq hereby grants to Licensee an exclusive (even as to Bioeq), milestone- and royalty-bearing, non-transferable license (including the right to grant sublicenses only to the extent permitted by [Section 2.1.2]) under the Licensed Technology (including the Licensed Patents) to use, sell, have sold, import, have imported or otherwise Commercialize the Licensed Products in the Field in the Territory.

Non-Exclusive License. Subject to the terms and conditions of this Agreement, Allogene hereby grants to [[Cellectis:Organization]] and its Affiliates a non-exclusive, worldwide, royalty-free, perpetual and irrevocable license under the Licensed Allogene Intellectual Property Controlled by Allogene solely to make, have made, use, have used, sell, have sold, offer for sale, have offered for sale, import, have imported and otherwise exploit and Commercialize [[Cellectis:Organization]] Products Targeting [[Cellectis:Organization]] Program Targets. [[Cellectis:Organization]] will have the right to grant sublicenses of the foregoing license to Third Party collaborators only if [[Cellectis:Organization]] has entered into a written agreement with such Third Party collaborator # obtaining a covenant not to sue or # granting Allogene a non-exclusive, worldwide, royalty-free, perpetual and irrevocable license under improvements to the [[Cellectis:Organization]] Technology developed in the framework of the collaboration between [[Cellectis:Organization]] and such Third Party that are Controlled by such Third Party.

The license granted in Section 2.2.1, shall be exclusive with respect to ​ in each jurisdiction within the Territory from the Effective Date until the earlier of: # ​ after ​ of the Product as an ​ in the applicable jurisdiction; and # ​ following the Effective Date (the “Exclusive License Period”).

Exclusive License Grant. Subject to the terms and conditions of this Agreement, Xenon hereby grants to Neurocrine an exclusive (even as to Xenon and its Affiliates), royalty bearing license, with the right to grant sublicenses through multiple tiers as set forth in Section 2.3, under the Xenon Licensed IP, subject to the Xenon Retained Rights set forth in Section 2.2, to research, Develop, make, have made, use, sell, offer for sale, import, export and otherwise exploit and Commercialize the Compounds and Products in the Field in the Territory. Such license is subject to the non-exclusive license under certain of the Xenon Licensed IP that is granted to Genentech in the Genentech License for internal research purposes. The Parties acknowledge that certain of the Xenon Know-How includes Know-How non-exclusively licensed to Xenon from Genentech under the Genentech License, and that accordingly Neurocrine’s sublicense thereunder is exclusive with respect to Xenon (subject to Section 2.2) and not with respect to Genentech.

Exclusive License Grant. Subject to the terms and conditions of this Agreement (including [Section 2.4] (Retained Rights)), Licensor hereby grants to Licensee an exclusive (even as to Licensor, subject to [Section 2.4] (Retained Rights)), sublicensable (subject to [Section 2.2] (Sublicense Rights)), royalty-bearing license during the Term under the Licensor Technology to Exploit the Licensed Compounds and Licensed Products in the Field in the Territory.

The parties acknowledge and agree that they intend to use their reasonable best efforts to complete the Research Project as described in the Study Protocol. In the event the Company and its Affiliates and partners elect to discontinue to pursue the development and/or commercialization of a Research Product for reasons other than safety and efficacy, the Company and its Affiliates, at the request of the Sponsor, hereby grants the Sponsor the exclusive royalty-bearing, fully paid up, worldwide license or sublicense as the case may be, with the right to sublicense, to the Research Product, on terms consistent with the requirements of the Ercole Biotech-Isis Pharmaceuticals collaboration agreement and Ercole Biotech-AVI BioPharma collaboration agreement, under patents owned or licensed by the Company or its Affiliates to research, to develop, to use, to sell, to offer for sale, to distribute Research Products, to import, to export and to employ methods covered by any such patents or by Company Inventions or

Exclusive License to Sunesis. Subject to the terms and conditions of this Agreement, Biogen Idec hereby grants to Sunesis a worldwide, exclusive license under the [[Unknown Identifier]] Technology, with the right to grant and authorize sublicenses as provided in Section 6.5, to develop, make, have made, use, import, offer for sale, sell and otherwise exploit [[Unknown Identifier]] and [[Unknown Identifier]] Products in the Oncology Field (the “[[Unknown Identifier]] Exclusive License”).

Exclusive License Grant to Acadia. Subject to the terms and conditions of this Agreement, on a [[Unknown Identifier]] Co-Co Product-by-SYNGAP1 Co-Co Product basis, Stoke (on behalf of itself and its Affiliates) hereby grants to Acadia a co- exclusive (with Stoke and its Affiliates), non-transferable (except as set forth in [Section 17.1(a)]), sublicensable (as set forth in Section 2.2), license under the Stoke [[Unknown Identifier]] Technology to Develop, make, have made, use, sell, offer for sale, import, Commercialize (for avoidance of doubt, including Medical Affairs activities) and otherwise Exploit such [[Unknown Identifier]] Co-Co Product in the Field in the Territory. Stoke retains the right (on behalf of itself and its Affiliates) to practice the [[Unknown Identifier]] Technology to exercise its rights and perform its obligations hereunder and as set forth in [Section 2.3].